NCT06423586View on ClinicalTrials.gov

Effect of Lecithin-based Curcuma and Boswellia on Post-acute COVID-19 IBS

NACompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

October 1, 2021

Study Completion Date

June 10, 2022

Conditions
Post-Acute COVID-19 SyndromeIrritable Bowel SyndromeAbdominal PainDysbiosis
Interventions
DIETARY_SUPPLEMENT

Curcuma longa and Boswellia serrata extracts

Participants received 500 mg of Curcuma longa and 150 mg of Boswellia serrata extracts (Meriva™ and Casperome™) twice daily for 30 days.

Trial Locations (1)

27100

Mariangela Rondanelli, Pavia

All Listed Sponsors
lead

Azienda di Servizi alla Persona di Pavia

OTHER

NCT06423586 - Effect of Lecithin-based Curcuma and Boswellia on Post-acute COVID-19 IBS | Biotech Hunter | Biotech Hunter